Solid Biosciences Inc（SLDB）の株式分析SLDBSolid Biosciences Inc

Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. It also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Solid Biosciences Inc is currently a hold due to its low current price of $5.53 and a concerning RSI of 20.262, indicating oversold conditions. However, the company has a strong cash position of $380.7 million, which supports its ongoing R&D efforts. The main risk is the negative sentiment reflected in the recent insider selling, which has increased by 6640.99% over the last month, suggesting a lack of confidence from insiders.

5 analysts cover SLDB: 3 rate it Buy, 1 Hold and 1 Sell. The average price target is 14.88.